8-K: Celcuity Reports Unprecedented Phase 3 Data, Secures $286.5M

Celcuity Inc. announced positive Phase 3 clinical trial data for gedatolisib in breast cancer, secured significant financing, and reported increased operating expenses for Q2 2025.

Summary

• Reported statistically significant and clinically meaningful improvement in both primary endpoints from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial.
• Hazard ratios and improvements in median progression-free survival (PFS) are unprecedented in HR+/HER2advanced breast cancer (ABC).
• Expect to submit a New Drug Application (NDA) for gedatolisib, based on data from the PIK3CA wild-type cohort, to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025.
• Completed concurrent offerings of convertible notes, common stock, and pre-funded warrants, with net proceeds of $286.5 million.
• On a proforma basis, cash, cash equivalents, and short-term investments totaled $455 million as of the end of Q2 2025, expected to fund operations through 2027.
• Total operating expenses increased to $44.0 million for Q2 2025 from $24.3 million for Q2 2024.
• Net loss for Q2 2025 was $45.3 million, or $1.04 loss per share, compared to a net loss of $23.7 million, or $0.62 loss per share, for Q2 2024.

Sentiment

Score: 9

Explanation: The filing presents overwhelmingly positive clinical trial results for gedatolisib, particularly the "unprecedented" efficacy in Phase 3 VIKTORIA-1, which is a major de-risking event. The successful capital raise significantly strengthens the balance sheet and extends the cash runway, while the new patent provides long-term market exclusivity. Although operating expenses and net loss increased, this is expected for a company advancing multiple clinical programs towards commercialization.

Positives

• Statistically significant and clinically meaningful improvement in primary endpoints from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial for gedatolisib.
• Unprecedented hazard ratios and improvements in median progression-free survival (PFS) in HR+/HER2advanced breast cancer (ABC) for gedatolisib.
• Gedatolisib triplet reduced risk of disease progression or death by 76% (HR 0.24) with median PFS of 9.3 months, an improvement of 7.3 months over fulvestrant alone.
• Gedatolisib doublet reduced risk of disease progression or death by 67% (HR 0.33) with median PFS of 7.4 months, an improvement of 5.4 months over fulvestrant alone.
• Lower rates of hyperglycemia and stomatitis and lower discontinuation due to treatment-related adverse events compared to a Phase 1b study.
• First patient dosed in Phase 3 VIKTORIA-2 clinical trial for first-line HR+/HER2ABC.
• Positive topline data from Phase 1b portion of CELC-G-201 study in mCRPC, showing 66% six-month radiographic PFS rate and no treatment discontinuations due to AEs.
• Objective response rate of 43% in Phase 2 trial for HER2+/PIK3CA mutated mBC with gedatolisib plus trastuzumab-pkrb.
• New patent for gedatolisib dosing regimen issued, extending exclusivity into 2042.
• Successful completion of concurrent offerings raising $286.5 million in net proceeds.
• Proforma cash position of $455 million as of Q2 2025, expected to fund operations through 2027.

Negatives

• Total operating expenses increased significantly to $44.0 million in Q2 2025 from $24.3 million in Q2 2024.
• Research and development expenses increased to $40.2 million in Q2 2025 from $22.5 million in Q2 2024, partly due to a $5.0 million anticipated development milestone payment.
• General and administrative expenses increased to $3.8 million in Q2 2025 from $1.8 million in Q2 2024.
• Net loss widened to $45.3 million, or $1.04 loss per share, in Q2 2025 from $23.7 million, or $0.62 loss per share, in Q2 2024.
• Net cash used in operating activities increased to $36.2 million in Q2 2025 from $18.1 million in Q2 2024.

Risks

• Topline results are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review.
• Unforeseen delays in clinical trials.
• Unforeseen delays in the planned New Drug Application (NDA) for gedatolisib.
• Ability to obtain and maintain regulatory approvals to commercialize gedatolisib.
• Market acceptance of gedatolisib.
• Development of therapies and tools competitive with gedatolisib.
• Ability to access capital upon favorable terms.

Future Outlook

Celcuity expects to submit a New Drug Application (NDA) for gedatolisib, based on data from the PIK3CA wild-type cohort of the VIKTORIA-1 trial, to the FDA in the fourth quarter of 2025. Topline data from the PIK3CA mutant cohort of VIKTORIA-1 is also anticipated in the fourth quarter of 2025. The company believes its recent financing and growing clinical data position it to advance multiple potential blockbuster indications in breast and prostate cancer, with current cash expected to fund operations through 2027.

Management Comments

• "We have had an eventful past few months at Celcuity. Last month, we announced positive topline data from the PIK3CA wild-type cohort of the pivotal Phase 3 VIKTORIA-1 clinical trial, which showed unprecedented reduction in risk of disease progression or death and incremental improvement in progression free survival in patients with HR+/HER2advanced breast cancer." Brian Sullivan, CEO and co-founder.
• "We believe topline data for both gedatolisib regimens from VIKTORIA-1 are potentially practice-changing." Brian Sullivan, CEO and co-founder.
• "We are on track to submit the New Drug Application for gedatolisib, based on data from the PIK3CA wild-type cohort, later this year and to report topline data from the PIK3CA mutant cohort in the fourth quarter of 2025." Brian Sullivan, CEO and co-founder.
• "Additionally, with our recent financing and our growing body of clinical data, we believe we are in a unique position to advance multiple potential blockbuster indications in breast and prostate cancer." Brian Sullivan, CEO and co-founder.

Industry Context

The positive Phase 3 data for gedatolisib in HR+/HER2advanced breast cancer, particularly the "unprecedented" hazard ratios and PFS improvements, positions Celcuity as a significant player in the oncology space, especially for a challenging breast cancer subtype. The expansion into first-line treatment and other indications like mCRPC and HER2+ mBC suggests a broad therapeutic strategy. The market for targeted therapies in oncology, particularly for breast and prostate cancers, is highly competitive but offers substantial opportunities for novel, effective treatments. The extended patent exclusivity into 2042 provides a strong competitive moat for gedatolisib.

Comparison to Industry Standards

• The reported hazard ratios (0.24 for triplet, 0.33 for doublet) and median PFS improvements (7.3 months for triplet, 5.4 months for doublet) over fulvestrant alone are described as "unprecedented in HR+/HER2advanced breast cancer (ABC)". This suggests gedatolisib's efficacy in this patient population significantly surpasses existing or historical benchmarks for similar treatment lines.
• The lower rates of hyperglycemia and stomatitis, and lower discontinuation due to treatment-related adverse events compared to a prior Phase 1b study, indicate a potentially improved safety profile or better management of side effects, which is a critical factor for patient adherence and quality of life compared to other PI3K inhibitors that have faced tolerability challenges.
• The 66% six-month radiographic progression-free survival rate in mCRPC from the CELC-G-201 study, with no discontinuations due to AEs, suggests a favorable efficacy and safety profile for gedatolisib in combination with darolutamide, potentially comparing favorably to current mCRPC treatment options.
• The 43% objective response rate in HER2+/PIK3CA mutated mBC with gedatolisib plus trastuzumab-pkrb indicates a promising activity in a specific, difficult-to-treat breast cancer subtype, potentially offering a new therapeutic avenue where options may be limited or less effective.

Stakeholder Impact

• Shareholders: Positive clinical trial results and extended patent exclusivity could lead to increased share value. Successful capital raise dilutes existing shareholders but provides necessary funding for continued development and potential commercialization.
• Patients: Gedatolisib offers a potentially "practice-changing" new treatment option with unprecedented efficacy for HR+/HER2advanced breast cancer, and promising results in mCRPC and HER2+ mBC, potentially improving outcomes and quality of life.
• Employees: Continued clinical progress and strong financial position provide job security and potential for growth within the company.
• Creditors: The successful convertible note offering and strong cash position enhance the company's ability to meet its financial obligations.
• Regulatory Authorities (FDA): The upcoming NDA submission will initiate a review process for potential market approval, impacting public health.

Next Steps

• Submit a New Drug Application (NDA) for gedatolisib, based on data from the PIK3CA wild-type cohort, to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025.
• Report topline data from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 trial in the fourth quarter of 2025.
• Present full data from the PIK3CA wild-type cohort of the VIKTORIA-1 clinical trial at an upcoming medical conference later this year.
• Present additional preliminary results from the Phase 1b portion of the CELC-G-201 study at a medical conference later this year.
• Continue enrollment in the PIK3CA mutant cohort of the VIKTORIA-1 trial.
• Continue enrollment in the Phase 3 VIKTORIA-2 clinical trial.
• Host a webcast and conference call on August 14, 2025, at 4:30 p.m. ET to discuss results and provide a corporate update.

Key Dates

Recommendation

The filing details "unprecedented" positive Phase 3 clinical trial results for gedatolisib in a significant breast cancer indication, which is a major de-risking event for a clinical-stage biotech. The successful capital raise of $286.5 million significantly bolsters the balance sheet, extending the cash runway through 2027, and a new patent extends market exclusivity to 2042. These factors, combined with multiple ongoing trials in other high-value indications and an anticipated NDA submission, suggest strong future growth potential and a highly favorable risk-reward profile for investors, despite increased operating losses typical of a development-stage company.

Keywords

Celcuity, CELC, Gedatolisib, Oncology, Breast Cancer, Prostate Cancer, PIK3CA, VIKTORIA-1, VIKTORIA-2, Clinical Trial, Phase 3, FDA NDA, Biotechnology, Financial Results, Q2 2025, Drug Development, Targeted Therapy, HR+/HER2ABC, mCRPC, HER2+ mBC, Patent, Capital Raise